Navigation Links
Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa
Date:7/1/2009

>

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the plans for, the potential of and the potential market for corifollitropin alfa . Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including the regulatory process for approval of corifollitropin alfa among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part II, Item IA. "Risk Factors" in Schering-Plough's first quarter 2009 10-Q, filed May 1, 2009.

Endnotes

  1. Fernandez-Sanchez M et al, Equally high ongoing pregnancy rates with corifollitropin alfa and recombinant FSH irrespective of variations in ART procedures. Oral presentation at 25th European Society of
    '/>"/>

SOURCE Schering-Plough
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... BOULDER, Colo., December 10, 2009 miRagen Therapeutics, ... lives by developing innovative microRNA-based therapeutics for cardiovascular ... data demonstrating that microRNA-206 (miR-206) plays a crucial ... (ALS or Lou Gehrig,s disease) and in neuromuscular ... in the December 11 issue of the journal ...
(Date:12/11/2009)... Boston College researchers have observed the "hot electron" ... and successfully harvested the elusive charges using ultra-thin solar ... efficiency, the authors report in the current online edition ... is captured in solar cells, it generates free electrons ... to snare these charges, the electrons must reach the ...
(Date:12/11/2009)... Algeta ASA (OSE: ALGETA), the,cancer ... center in the,US, the Tulane Cancer Center, ... phase III clinical study of Alpharadin in ... cancer,(CRPC) that has metastasized to the skeleton. ... (ALpharadin in SYMptomatic Prostate CAncer) study is ...
(Date:12/11/2009)... Mass., Dec. 11 Gwathmey, Inc., ... specializing in cancer, staph aureus, and cardiovascular disease ... Services announced today that Rosalie Dunn, Ph.D., has ... Dunn has over 28 years of experience working ... Prior to joining Gwathmey, Dr. Dunn managed multimillion ...
Breaking Biology Technology:miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2Elusive 'hot' electrons captured in ultra-thin solar cells 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer 2
... 7 GlaxoSmithKline plc (LSE/NYSE: GSK ) ... by its wholly-owned subsidiary Gemstone Acquisition Corporation for shares ... GNLB ). The tender offer expired at 12:00 ... 2009.The depositary for the tender offer has advised GSK ...
... Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical ... Company will present,data from two ongoing Phase 2 clinical ... Oncology (ASCO) Symposia. , In ... Phase 2 trial,of picoplatin in patients with metastatic colorectal ...
... Jan. 7 Dr. Ryan Burnette, Director of Alliance ... 19, 2009 through January 23, 2009. Dr. Burnette ... for high-containment biomedical labs as a lynchpin to an ... excited to visit Singapore, a progressive country that has ...
Other Biology Technology:GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc. 2Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers 2Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers 3Alliance Biosciences Announces Trade Mission to Singapore with Speaker Presentation at International Lab Design Seminar 2Alliance Biosciences Announces Trade Mission to Singapore with Speaker Presentation at International Lab Design Seminar 3
(Date:12/14/2009)... is in preventing some of the stresses of open surgery ... flow and organ dysfunction. Laparoscopy is a type of surgery ... , By adding another gas to the carbon dioxide ... Duke University Medical Center have found they can preserve more ... ethyl nitrite (ENO) helped to open blood vessels and keep ...
(Date:12/13/2009)... discovered five genetic variants that are associated with the ... international consortium of 96 scientists from 63 centres in ... basis of lung diseases. , The new findings provide ... Obstructive Pulmonary Disease (COPD) and asthma. In the past ... the molecular pathways that affect the health of the ...
(Date:12/11/2009)... COLLINS, COWild Malus orientalis species of wild apples ... native to the Middle East and Central Asia. A ... M. orientalis varieties from Georgia and Armenia with ... the large population and establishes a core collection that ... the breeding and research communities. , To identify and ...
Breaking Biology News(10 mins):Gas improves blood flow and organ status during minimally invasive surgery 2New genes for lung disease discovered 2Understanding apples' ancestors 2AUDIO from Medialink and Majestic Drug Company 3A When the Tooth Hurts 60261 1Shu Tung Li Founder and CEO of Collagen Matrix Inc Honored as 2009 New Jersey Executive of the Year Finalist and Company Named One of Fifty Fastest 60257 1Shu Tung Li Founder and CEO of Collagen Matrix Inc Honored as 2009 New Jersey Executive of the Year Finalist and Company Named One of Fifty Fastest 60257 2Jedi Mind Inc in Excellent Financial Shape to Expand Business 60253 1Jedi Mind Inc in Excellent Financial Shape to Expand Business 60253 2
... white oak were once widespread in the Pacific Northwests ... suppression, conifer and invasive plant encroachment, and land use ... as 99 percent of the oak communities historically present ... technical report titled "Evaluation of Landscape Alternatives for Managing ...
... and technological advances, which tend to take their place ... of public debate and regulatory attention, due partly to ... , In this second BBVA Foundation international study ... the sample has been enlarged from nine to twelve ...
... Its a paradox that has confounded evolutionary biologists since ... Since parasites depend on their hosts for survival, why do ... Emory University study of monarch butterflies and the microscopic parasites ... strike a middle ground between the benefits gained by reproducing ...
Other Biology News:BBVA Foundation international study on attitudes to stem cell research 2BBVA Foundation international study on attitudes to stem cell research 3BBVA Foundation international study on attitudes to stem cell research 4BBVA Foundation international study on attitudes to stem cell research 5BBVA Foundation international study on attitudes to stem cell research 6Monarch butterflies help explain why parasites harm hosts 2Monarch butterflies help explain why parasites harm hosts 3
... generated hybridomas against a large variety ... you are provided with personalized project ... lines developed by Covance remain exclusive ... hybridoma development project has four phases: ...
Cells are grown in triple flasks or roller bottles. Viability and growth data are generated from a parallel representative culture....
... The Human Genetic Cell Bank Service ... ECACC is based on Epstein-Barr Virus (EBV) ... resulting in the production of lymphoblastoid cell ... banked, providing a renewable and expandable source ...
... Extracts are optimized for maximum packaging efficiencies ... high efficiency extracts (> 109 pfu/g with ... a library containing at least 5 ... extracts are made from a specially designed ...
Biology Products: